| HOME >> BIOLOGY >> TECHNOLOGY |
Overall Market Growth Will be Driven by Launch of Nine Emerging Therapies,
Including Five Oral Agents, According to a New Report from Decision
Resources
WALTHAM, Mass., May 29 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the highly anticipated launch of the first oral agents formally approved for multiple sclerosis will drive market growth as these therapies, combined, will garner 25 percent market share in 2017.
The new Pharmacor report entitled Multiple Sclerosis estimates that Novartis/Mitsubishi Tanabe's oral agent, FTY-720 (fingolimod) will capture nearly $900 million by 2017 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan, representing the greatest market share of any emerging multiple sclerosis therapy over the next decade. The report finds that, despite limited patient share, sales of FTY-720 will be driven by its improved efficacy, acceptable safety profile, and added convenience. The launch of nine emerging therapies-including five oral drugs-will drive moderate four percent annual growth through 2017 in the multiple sclerosis drug market. Rapid uptake of premium-priced oral drugs and the growing use of monoclonal antibodies, particularly in the United States, will spark this growth.
The report also finds that other strong contenders in the multiple
sclerosis market over the next 10 years will include Merck Serono's oral
cladribine (Mylinax), BioMS Medical/Eli Lilly's MBP-8298, and alemtuzumab,
which is marketed in the U.S. as Campath for B-cell chronic lymphocytic
leukemia by Bayer HealthCare and Genzyme Oncology. Oral cladribine's
first-to- market status among emerging oral agents, MBP-8298's approval for
secondary progressive multiple sclerosis and alemtuzumab's impressive
efficacy will drive major-market peak-year sales for each drug to the range
of $500 millio
'/>"/>
| SOURCE Decision Resources Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. Biological electron transfer captured in real time
2. AbelsonTaylor Captures DTC Gold
3. Safety Profile of TAXUS(R) Liberte(TM) Stent System Highlighted in Worlds Largest Stent Registry
4. Largest Asian Cancer Hospital to Evaluate New CT Laser Breast Imaging System
5. Researchers outline structure of largest nonvirus particle ever crystallized
6. Medco Chooses AllPoints at Anson in Whitestown, Indiana as Site for the Worlds Largest, Most-Advanced Automated Pharmacy
7. The LANCET Published ENDORSE, the Largest Multinational Study Showing That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE Prophylaxis
8. Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History
9. ChanTest to Highlight Expanded Ion Channel Testing Services for Preclinical Safety at ToxExpo, Including the Worlds Largest Catalog of Validated Ion Channels, Booth 2504
10. Susan G. Komen for the Cure(R) Announces Largest Grants Slate Ever: $100 Million to Speed Delivery of Breast Cancer Discoveries, Cures
11. Cepheid Signs Group Purchasing Contract with Novation, the Nations Largest Healthcare Contracting Organization
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |